Oncology – Medxy AI

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

By MedXY 03/09/2026

The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signatures as a key predictor of response.

Gastroenterology news Oncology

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling

By MedXY 03/08/2026

Researchers have identified DARS1 as a critical oncogenic driver in hepatocellular carcinoma. Beyond its role in protein synthesis, DARS1 enters the nucleus to modulate MYC signaling through the SAGA complex, offering a new therapeutic vulnerability and a potential liquid biopsy biomarker.

Gastroenterology news Oncology

The Tryptophan Tug-of-War: How Faecalibacterium prausnitzii Counteracts Bacteroides fragilis in Colorectal Cancer

By MedXY 03/08/2026

A comprehensive multi-omics study reveals that Faecalibacterium prausnitzii metabolizes tryptophan into picolinic acid, which antagonizes the pro-tumorigenic effects of enterotoxigenic Bacteroides fragilis by down-regulating TCERG1 and CKAP2 genes, suggesting a potential dietary intervention for colorectal cancer.

Gastroenterology news Oncology

Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort

By MedXY 03/07/2026

This international multicenter study demonstrates that adjuvant imatinib therapy significantly improves both recurrence-free and overall survival in patients with resected KIT exon 9-mutant GIST, providing clarity on optimal management for this biologically distinct subgroup.

Clinical Updates news Oncology

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling

By MedXY 03/07/2026

This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT1/STAT3 modulation.

Diabetes & Endocrinology news Oncology

Beyond Mandatory Resection: Active Surveillance Proves Safe for RAS-Positive Thyroid Nodules

By MedXY 03/06/2026

A new study suggests that isolated RAS mutations in Bethesda III and IV thyroid nodules do not always require surgery. With a 34% malignancy rate and low growth incidence, active surveillance emerges as a viable, safe alternative for appropriately selected patients.

$Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program$

Clinical Updates news Oncology

Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program

By MedXY 03/06/2026

This review synthesizes findings from the Australian MoST program, demonstrating that genomically matched therapies significantly improve overall survival in advanced solid tumors only when supported by high-level prospective clinical trial evidence.

Clinical Updates news Oncology

Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial

By MedXY 03/06/2026

A secondary analysis of the GAP70+ trial reveals that while 71.7% of older adults with advanced cancer prioritize quality of life, their clinical outcomes—including survival and toxicity—remain unchanged compared to those prioritizing survival, suggesting a systemic lack of responsiveness to patient goals.

news Oncology Urology

Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy

By MedXY 03/06/2026

A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standards for recurrent prostate cancer.

Dermatology news Oncology

Breaking the Wall: Can Intermittent Chemotherapy Overcome Primary Checkpoint Inhibitor Resistance in Metastatic Melanoma?

By MedXY 03/05/2026

The multicentre phase II PROMIT trial demonstrates that intermittent dacarbazine can sensitize BRAF wildtype metastatic melanoma patients with primary ICI resistance to subsequent ICI rechallenge, yielding an 18% objective response rate and a manageable safety profile.

news Oncology Urology

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease

By MedXY 03/04/2026

The SURE-02 phase 2 trial demonstrates that a combination of sacituzumab govitecan and pembrolizumab achieves a 39% clinical complete response rate in muscle-invasive bladder cancer, offering a promising bladder-sparing alternative for patients ineligible for cisplatin-based chemotherapy.

Gastroenterology news Oncology

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers

By MedXY 03/04/2026

A multicentre cohort study confirms that upfront 30% irinotecan dose reductions for UGT1A1 poor metabolisers effectively prevent severe toxicity without compromising progression-free or overall survival in colorectal and pancreatic cancer patients.

Cardiology news Oncology

The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension

By MedXY 03/01/2026

Emerging evidence identifies a bidirectional link between breast cancer and pulmonary arterial hypertension (PAH) driven by BMPR2 signaling and IL-1β-mediated inflammation. This study suggests breast cancer may serve as a critical second hit, unmasking latent vascular susceptibility in at-risk populations.

Clinical Updates news Oncology Otorhinolaryngology

Surgical Management of Sporadic Medullary Thyroid Cancer: Evidence-Based Comparison of Total Thyroidectomy vs Lobectomy

By MedXY 02/27/2026

This systematic review and meta-analysis suggests that thyroid lobectomy may offer comparable oncologic outcomes to total thyroidectomy for selected patients with sporadic medullary thyroid cancer, while significantly reducing postoperative complications.

news Oncology Otorhinolaryngology

Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma

By MedXY 02/27/2026

A Phase 2 clinical trial of amivantamab, an EGFR-MET bispecific antibody, in recurrent or metastatic adenoid cystic carcinoma (ACC) showed a 72.2% clinical benefit rate. While the primary objective response rate was low, the high rate of disease stabilization highlights its potential in managing this rare malignancy.

news Oncology Otorhinolaryngology

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma

By MedXY 02/27/2026

Long-term results from the RATIONALE-309 trial show tislelizumab plus chemotherapy significantly improves survival in recurrent or metastatic nasopharyngeal carcinoma, establishing a durable therapeutic standard and identifying B-cell signatures as key biomarkers for treatment response.

Clinical Updates news Oncology

Optimizing Adjuvant Therapy for KIT Exon 9-Mutated Gastrointestinal Stromal Tumors: Evidence from a Global Multicenter Synthesis

By MedXY 02/26/2026

This review synthesizes the latest evidence on adjuvant imatinib for KIT exon 9-mutated GISTs, highlighting the landmark 2026 international study that confirms improved survival and challenges previous dosing paradigms in the adjuvant setting.

Dermatology news Oncology

KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients

By MedXY 02/26/2026

The Phase 3 KEYVIBE-010 trial demonstrates that adding vibostolimab to pembrolizumab in the adjuvant setting for melanoma does not improve outcomes, instead yielding a higher recurrence rate and increased toxicity, reinforcing pembrolizumab monotherapy as the standard of care.

news Oncology Radiology

MRI-Guided Personalization of Chemotherapy for HER2-Positive Breast Cancer: Insights from the TRAIN-3 Trial

By MedXY 02/26/2026

The TRAIN-3 study reveals that using MRI to monitor treatment response allows for shorter chemotherapy durations in HER2-positive breast cancer patients, achieving high 3-year event-free survival while significantly reducing toxicity and improving patient quality of life.

Clinical Updates news Oncology Radiology Urology

Risk Stratification in PSMA PET-Staged Oligorecurrent Prostate Cancer: Clinical Synthesis of the PORTAL Nomogram and Metastasis-Directed Therapy

By MedXY 02/26/2026

This review analyzes the PORTAL study’s nomogram for predicting ADT-free survival in oligorecurrent prostate cancer, synthesizing evidence on PSMA PET-guided SBRT and the clinical utility of risk-based patient selection.